LEADER 00000cam a2200745Ii 4500
001 ocn898894164
003 OCoLC
005 20170728052058.3
006 m o d
007 cr |||||||||||
008 141229t20152015nyua ob 001 0 eng d
019 899158351
020 9781617051067|q(electronic book)
020 1617051063|q(electronic book)
020 |z9781936287598|q(print)
020 |z1936287595|q(print)
035 (OCoLC)898894164|z(OCoLC)899158351
040 N$T|beng|erda|epn|cN$T|dYDXCP|dN$T|dE7B|dOCLCF|dEBLCP
|dOCLCO|dMMU|dOCLCO|dOCLCQ|dOCLCO|dD6H|dLVT|dCOCUF|dCNNOR
|dMOR|dCCO|dPIFAG|dZCU
049 RIDW
050 4 RC280.P7
072 7 HEA|x039030|2bisacsh
072 7 MED|x062000|2bisacsh
082 04 616.99/463|223
090 RC280.P7
130 0 Prostate cancer (Dicker)
245 10 Prostate cancer :|ba multidisciplinary approach to
diagnosis and management /|cedited by Adam P. Dicker,
William Kevin Kelly, Nicholas G. Zaorsky, Edouard J.
Trabulsi ; illustrations by Nicholas G. Zaorsky.
264 1 New York :|bDemosMedical,|c[2015]
264 4 |c©2015
300 1 online resource (xxi, 412 pages) :|billustrations (some
color).
336 text|btxt|2rdacontent
337 computer|bc|2rdamedia
338 online resource|bcr|2rdacarrier
347 text file|2rdaft
490 1 Current multidisciplinary oncology series
504 Includes bibliographical references and index.
505 0 Part I: Epidemiology, screening, and diagnosis --
Introduction: the multidisciplinary approach to prostate
cancer -- Epidemiology of prostate cancer -- Diet and
prostate cancer -- Epidemiology: obesity as a risk factor
-- Screening and diagnosis: the pros of PSA screening --
The argument against prostate cancer screening -- How do
we improve PSA accuracy? -- Screening and diagnosis: an
update on the ISUP-modified Gleason score and its
controversies -- Evaluation of distant disease: the
utility of nuclear imaging -- Current approaches to
prostate cancer staging and risk stratification: in the
midst of a paradigm shift -- Novel molecular and genotype
profiling in prostate cancer: the future of screening,
diagnosis, and staging -- Genomics and risk assessment --
Future direction: novel urine and serum markers --
Morphometric and systems pathology: the future of
screening, diagnosis, and staging -- PET: the future of
screening, diagnosis, and staging for prostate cancer --
DCE MRI and MR spectroscopy: the future of screening,
diagnosis, and staging -- Future direction: contrast
ultrasound -- Counseling patients with clinically
localized, high-risk prostate cancer -- Part II: Treatment
for low-risk, localized disease -- Active surveillance for
prostate cancer: an overview -- Treatment of low-risk,
localized prostate cancer: a holistic approach with diet -
- Traditional radical prostatectomy -- Laparoscopic
radical prostatectomy: techniques and complications --
Robotic radical prostatectomy: the Thomas Jefferson
University experience -- Surgical training, digital
capture, virtual reality, and the future of radical
prostatectomy -- External beam radiation therapy:
conventional fractionation -- Hypofractionated radiation
therapy for localized prostate cancer -- Stereotactic body
radiation therapy for localized prostate cancer --
Treatment of low-risk, localized prostate cancer: use of
proton therapy -- Treatment of low-risk, localized
prostate cancer: brachytherapy -- Treatment of low-risk,
localized prostate cancer: general principles of ablative
and focal therapies -- Hyperthermia for prostate cancer --
Ablative techniques: vascular targeted photodynamic
therapy -- Laser ablative techniques for prostate cancer -
- Irreversible electroporation (IRE) prostate ablation --
Quality of life with surgery -- Quality of life with
androgen deprivation therapy -- Quality of life with
external beam radiation therapy -- Quality of life with
brachytherapy for low-risk localized prostate cancer --
Role for comparative effectiveness research in treatment
decision making -- Defining treatment failure for
localized prostate cancer: PSA and beyond -- Prognosis
after biochemical failure and surrogate endpoints for
prostate cancer-specific mortality -- Part III: Treatment
for high-risk, localized, and locally advanced disease --
treatment of high-risk prostate cancer: the role of low-
dose rate (LDR) and high-dose rate (HDR) brachytherapy --
Part IV: Treatment of disseminated disease -- Salvage
therapy for rising PSA -- Metastatic hormone sensitive
prostate cancer -- Metastatic castrate-resistant prostate
cancer: mechanisms of hormone escape -- Metastatic
castrate-resistant prostate cancer: role of chemotherapy
and multifaceted treatment paradigms -- Metastatic
castrate-resistant prostate cancer: role of androgen
signaling inhibitors -- Radiation and the immune system --
Immunotherapy: agents targeting prostate cancer --
Treatment of bony metastases: inhibitors of bone
resorption -- Treatment of bone metastases:
radiopharmaceuticals -- Prognostication of metastatic
castration-resistant prostate cancer.
520 "With an emphasis on multidisciplinary collaboration and
decision-making, this practical resource reflects the
extraordinary advances in the treatment of prostate cancer
during the past five years. Approximately thirty
international, leading-edge investigators describe the
most current evidence-based approaches to prostate cancer
treatment. The book provides a comprehensive view of the
entire spectrum of prostate cancer management from initial
screening through novel and experimental treatments that
have the potential for a major impact on practice"--
Publisher's description.
588 0 Online resource; title from resource home page (ebrary,
viewed November 2, 2015).
590 eBooks on EBSCOhost|bEBSCO eBook Subscription Academic
Collection - North America
650 0 Prostate|xCancer|xDiagnosis.|0https://id.loc.gov/
authorities/subjects/sh2010010107
650 0 Prostate|xCancer|xTreatment.|0https://id.loc.gov/
authorities/subjects/sh2010010207
650 0 Health care teams.|0https://id.loc.gov/authorities/
subjects/sh85059533
650 7 Prostate|xCancer|xDiagnosis.|2fast|0https://
id.worldcat.org/fast/1079483
650 7 Prostate|xCancer|xTreatment.|2fast|0https://
id.worldcat.org/fast/1079496
650 7 Health care teams.|2fast|0https://id.worldcat.org/fast/
952868
650 12 Prostatic Neoplasms|xdiagnosis.|0https://id.nlm.nih.gov/
mesh/D011471Q000175
650 22 Early Detection of Cancer.|0https://id.nlm.nih.gov/mesh/
D055088
650 22 Patient Care Team.|0https://id.nlm.nih.gov/mesh/D010348
650 22 Prognosis.|0https://id.nlm.nih.gov/mesh/D011379
650 22 Prostate-Specific Antigen.|0https://id.nlm.nih.gov/mesh/
D017430
650 22 Prostatic Neoplasms|xtherapy.|0https://id.nlm.nih.gov/mesh
/D011471Q000628
655 4 Electronic books.
700 1 Dicker, Adam P.,|0https://id.loc.gov/authorities/names/
nb2004312350|eeditor.
700 1 Kelly, Wm. Kevin|q(William Kevin),|0https://id.loc.gov/
authorities/names/n2009184487|eeditor.
700 1 Zaorsky, Nicholas G.,|0https://id.loc.gov/authorities/
names/n2014187711|eeditor,|eillustrator.
700 1 Trabulsi, Edouard J.,|0https://id.loc.gov/authorities/
names/n2014187713|eeditor.
776 08 |iPrint version:|tProstate cancer.|dNew York : Demos,
[2015]|z9781936287598|w(DLC) 2014033133|w(OCoLC)888347032
830 0 Current multidisciplinary oncology.|0https://id.loc.gov/
authorities/names/n2009183517
856 40 |uhttps://rider.idm.oclc.org/login?url=http://
search.ebscohost.com/login.aspx?direct=true&scope=site&
db=nlebk&AN=933020|zOnline eBook. Access restricted to
current Rider University students, faculty, and staff.
856 42 |3Instructions for reading/downloading the EBSCO version
of this eBook|uhttp://guides.rider.edu/ebooks/ebsco
901 MARCIVE 20231220
948 |d20170802|cEBSCO|tebscoebooksacademic new
994 92|bRID
